306 related articles for article (PubMed ID: 33585182)
21. Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench.
Jin R; Zhao J; Xia L; Li Q; Li W; Peng L; Xia Y
Ther Adv Med Oncol; 2020; 12():1758835920930333. PubMed ID: 32565926
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future.
Rey-Cárdenas M; Guerrero-Ramos F; Gómez de Liaño Lista A; Carretero-González A; Bote H; Herrera-Juárez M; Carril-Ajuria L; Martín-Soberón M; Sepulveda JM; Billalabeitia EG; Castellano D; de Velasco G
Cancer Treat Rev; 2021 Feb; 93():102142. PubMed ID: 33453566
[TBL] [Abstract][Full Text] [Related]
23. [Innovations in systemic treatment of urothelial carcinoma].
Thibault C; Gross-Goupil M
Bull Cancer; 2020 Jun; 107(5S):S6-S16. PubMed ID: 32620209
[TBL] [Abstract][Full Text] [Related]
24. Erdafitinib to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2019 Aug; 55(8):495-501. PubMed ID: 31461086
[TBL] [Abstract][Full Text] [Related]
25. Combination Therapy as a Promising Way to Fight Oral Cancer.
Silva JPN; Pinto B; Monteiro L; Silva PMA; Bousbaa H
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376101
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapies in bladder cancer--an update.
Black PC; Agarwal PK; Dinney CP
Urol Oncol; 2007; 25(5):433-8. PubMed ID: 17826665
[TBL] [Abstract][Full Text] [Related]
27. Prime time for immunotherapy in advanced urothelial cancer.
Jiang DM; Sridhar SS
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():24-32. PubMed ID: 30489031
[TBL] [Abstract][Full Text] [Related]
28. Novel therapeutic targets in advanced urothelial carcinoma.
Rouanne M; Loriot Y; Lebret T; Soria JC
Crit Rev Oncol Hematol; 2016 Feb; 98():106-15. PubMed ID: 26589398
[TBL] [Abstract][Full Text] [Related]
29. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
Nagano T; Tachihara M; Nishimura Y
Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458
[TBL] [Abstract][Full Text] [Related]
30. The emergence of drug resistance to targeted cancer therapies: Clinical evidence.
Sarmento-Ribeiro AB; Scorilas A; Gonçalves AC; Efferth T; Trougakos IP
Drug Resist Updat; 2019 Dec; 47():100646. PubMed ID: 31733611
[TBL] [Abstract][Full Text] [Related]
31. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.
Mougel A; Terme M; Tanchot C
Front Immunol; 2019; 10():467. PubMed ID: 30923527
[TBL] [Abstract][Full Text] [Related]
33. Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.
Afonso J; Santos LL; Longatto-Filho A; Baltazar F
Nat Rev Urol; 2020 Feb; 17(2):77-106. PubMed ID: 31953517
[TBL] [Abstract][Full Text] [Related]
34. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
35. Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials.
Schmidt EV; Chisamore MJ; Chaney MF; Maradeo ME; Anderson J; Baltus GA; Pinheiro EM; Uebele VN
JAMA Netw Open; 2020 Feb; 3(2):e1920833. PubMed ID: 32049290
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment.
Zhao J; Chen Y; Ding ZY; Liu JY
Front Pharmacol; 2019; 10():1184. PubMed ID: 31680963
[TBL] [Abstract][Full Text] [Related]
37. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
Palakurthi S; Kuraguchi M; Zacharek SJ; Zudaire E; Huang W; Bonal DM; Liu J; Dhaneshwar A; DePeaux K; Gowaski MR; Bailey D; Regan SN; Ivanova E; Ferrante C; English JM; Khosla A; Beck AH; Rytlewski JA; Sanders C; Laquerre S; Bittinger MA; Kirschmeier PT; Packman K; Janne PA; Moy C; Wong KK; Verona RI; Lorenzi MV
Cancer Immunol Res; 2019 Sep; 7(9):1457-1471. PubMed ID: 31331945
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.
Karkera JD; Cardona GM; Bell K; Gaffney D; Portale JC; Santiago-Walker A; Moy CH; King P; Sharp M; Bahleda R; Luo FR; Alvarez JD; Lorenzi MV; Platero SJ
Mol Cancer Ther; 2017 Aug; 16(8):1717-1726. PubMed ID: 28416604
[TBL] [Abstract][Full Text] [Related]
39. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
40. Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
Robert L; Ribas A; Hu-Lieskovan S
Semin Immunol; 2016 Feb; 28(1):73-80. PubMed ID: 26861544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
